Clinical Trial

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-14.
Trial Details
NCT Number NCT07541833
Lead Sponsor Bristol-Myers Squibb
Conditions Cardiomyopathy
Enrollment 36 participants
Start Date 2026-02-05
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26